InvestmentPitch Media Video Discusses Hemostemix and its Hiring of 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal and Applying for Grants to Fund Up to 75% of 5-Year Expenses VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0), an autologous stem cell therapy company, is hiring four biotechnologists to...

InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01 VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has received a $250,000 Letter of Commitment for...